Potential predictive value of SCN4A mutation status for immune checkpoint inhibitors in melanoma

Weiyin Lin; Anqi Lin; Zhefu Li; Chaozheng Zhou; Chufeng Chen; Boliang Chen; Qingwen Lyu; Jian Zhang; Peng Luo

Biomedicine & Pharmacotherapy (Nov 2020)

Potential predictive value of SCN4A mutation status for immune checkpoint inhibitors in melanoma

Weiyin Lin,
Anqi Lin,
Zhefu Li,
Chaozheng Zhou,
Chufeng Chen,
Boliang Chen,
Qingwen Lyu,
Jian Zhang,
Peng Luo

Affiliations

Weiyin Lin: Department of Oncology, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, People’s Republic of China
Anqi Lin: Department of Oncology, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, People’s Republic of China
Zhefu Li: Central Sterile Supply Department, Integrated Hospital of Traditional Chinese Medicine, Southern Medical University, Guangzhou, Guangdong, People’s Republic of China
Chaozheng Zhou: Department of Oncology, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, People’s Republic of China
Chufeng Chen: Department of Oncology, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, People’s Republic of China
Boliang Chen: Department of Oncology, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, People’s Republic of China
Qingwen Lyu: Department of Information, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, People’s Republic of China; Guangdong Fusion Application Engineering Center of Medical Big Data, Guangzhou, Guangdong, People’s Republic of China; Corresponding author at: Department of Information, Zhujiang Hospital, Southern Medical University, 253 Industry Road, Guangzhou, 510282, People’s Republic of China.
Jian Zhang: Department of Oncology, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, People’s Republic of China; Corresponding authors at: Department of Oncology, Zhujiang Hospital, Southern Medical University, 253 Industry Road, Guangzhou, 510282, People’s Republic of China.
Peng Luo: Department of Oncology, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, People’s Republic of China; Corresponding authors at: Department of Oncology, Zhujiang Hospital, Southern Medical University, 253 Industry Road, Guangzhou, 510282, People’s Republic of China.

Journal volume & issue: Vol. 131
p. 110633

Abstract

Read online

Melanoma refers to a pigmented nevus with malignant changes. The preferred treatment for primary melanoma is surgical excision and postoperative radiotherapy, but the prognosis is poor. Immune checkpoint inhibitors (ICIs) have been remarkably successful in different types of cancers, but not all cancer patients can benefit from it. Therefore, it is essential to find predictable biomarkers and improve the accuracy of treatment. In this study, we used survival analysis, gene panorama analysis, immune cell enrichment analysis, TMB analysis, and GSEA to demonstrate that SCN4A gene mutations may be used as one of the indicators to predict the prognosis of melanoma patients undergoing ICI treatment. The research further indicates that SCN4A gene mutations improve the prognosis of ICI treatment. It is hoped that the effect of SCN4A on immunogenicity and tumor immunity can be demonstrated to further suggest the effect of this gene on the efficacy of ICIs.

Published in Biomedicine & Pharmacotherapy

ISSN: 0753-3322 (Print); 1950-6007 (Online)
Publisher: Elsevier
Country of publisher: France
LCC subjects: Medicine: Therapeutics. Pharmacology
Website: https://www.journals.elsevier.com/biomedicine-and-pharmacotherapy

About the journal

Abstract

Keywords